Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

PaperCitations, authors & open-access status

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 911 citations, 2007 year and closed oa status.

911
Citations
2007
Year
closed
OA Status

Related on ScholarIQ

Lesley Fallowfield
Author
The Lancet
Journal
Breast Cancer Treatment Studies
Topic
Breast Cancer Treatment Studies
Topic
Estrogen and related hormone effects
Topic
Advanced Breast Cancer Therapies
Topic
470M+ articles · free account